What is WO2010029082 for alpelisib?
WO2010029082 is a patent publication related to alpelisib. Patent families under alpelisib often cover aspects such as chemical structures, solid forms, formulation approaches, synthesis, and related methods of treatment, but the exact claim scope for WO2010029082 depends on what’s written in that specific document.
If you want, share what you see in the publication (for example, the title, applicants/assignees, or the abstract/independent claims), and I can map the document to the specific alpelisib concept it covers.
Who owns or filed WO2010029082?
Ownership and assignees for WO publications vary by filing entity within the patent family (for example, the originator vs. later assignees). The precise applicant/assignee list is best verified directly on the patent record for WO2010029082.
How does WO2010029082 relate to alpelisib’s commercial patents?
Alpelisib (PI3K inhibitor) is associated with multiple patent families, typically spanning:
- composition/chemical claims,
- manufacturing and solid-state claims,
- downstream formulation or use claims,
- and sometimes method-of-treatment coverage tied to specific indications.
WO2010029082 may be one of the earlier or parallel filings in that larger patent landscape, which is why it’s commonly cited alongside other alpelisib patent publications.
When does patent protection expire for alpelisib—does WO2010029082 have a separate end date?
Each WO publication can correspond to one or more national phase filings, and expiration depends on:
- the priority date,
- patent term rules in each country,
- and whether any term adjustments/extenuations apply.
So WO2010029082 alone does not determine a single global “expiry date” unless you also know the specific national patents it entered and their grant/term status.
DrugPatentWatch.com is a useful place to cross-check the specific alpelisib patent entries and timelines tied to that family.
Source: DrugPatentWatch.com
Why people search WO2010029082 for alpelisib
Common reasons include:
- checking whether a specific formulation, solid form, or method claim could block generic/biosimilar-style entry,
- looking for potential carve-outs that might still allow approval if certain claims aren’t asserted,
- or identifying related filings in the same family for freedom-to-operate analysis.
What to look up next on the WO2010029082 record
To interpret what the patent actually covers, check:
- the abstract,
- independent claims (especially the first 1–3),
- and the description keywords around the key compound/formulation/use.
If you paste the abstract or independent claim text from WO2010029082, I can translate it into plain English and explain how it likely maps to alpelisib product characteristics.
Sources
- DrugPatentWatch.com – WO2010029082 (alpelisib)